Tenaya Therapeutics, Inc. (TNYA)

In May 2026, Tenaya reported its Q1 2026 financial results, including a Q1 loss and revenue that missed estimates, and announced an expanded research collaboration with Alnylam Pharmaceuticals. In April 2026, Tenaya announced a late-breaking oral presentation of new clinical data from the RIDGE™-1 Phase 1b/2 clinical trial of TN-401 gene therapy at ASGCT 2026. In March 2026, the company reported Fourth Quarter and Full Year 2025 financial results and presented preclinical data at MDA 2026 highlighting TN-301's potential in Duchenne muscular dystrophy. In December 2025, Tenaya reported positive initial data from the RIDGE-1 Phase 1b/2 clinical trial of TN-401, the FDA removed a clinical hold on the MyPEAK-1™ Phase 1b/2a clinical trial of TN-201, and the company completed an underwritten public offering of units, raising approximately $60 million. In November 2025, Tenaya presented promising data from the MyPEAK-1 Phase 1b/2 clinical trial for TN-201.

The demand for Tenaya Therapeutics' products and services is not subject to typical seasonal fluctuations. Demand will primarily be driven by the prevalence of the targeted heart conditions, the success and progression of its clinical trials, and eventual regulatory approvals and commercialization.

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing curative therapies for heart disease, operating within the Healthcare sector, specifically in the Biotechnology industry. The company utilizes three product platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine, to address both rare genetic disorders and prevalent heart conditions. Its major product candidates in clinical development include TN-201, an AAV9-based gene therapy for MYBPC3-associated HCM; TN-401, an AAV9-based gene therapy for PKP2-associated ARVC; and TN-301, a small molecule HDAC6 inhibitor for heart failure and related cardio/muscular diseases.

Tenaya Therapeutics is headquartered in South San Francisco, California, United States. The company conducts its clinical trials in the U.S. and the UK.

Tenaya Therapeutics' brand reputation has been influenced by its clinical trial progress and financial activities. Positive interim clinical data for its gene therapy programs and the removal of a clinical hold on the MyPEAK-1 trial for TN-201 have contributed positively to its reputation. However, the company's reputation may have faced challenges from events such as a workforce reduction in April 2025 and the announcement of Q1 2026 revenue significantly below expectations.

Tenaya Therapeutics, Inc. is owned by a mix of institutional shareholders (31.61%), insiders (38.17%), and retail investors (30.22%). Major institutional owners include Column Group LLC, Vanguard Group Inc, and BlackRock, Inc. The largest individual shareholder is Column Group III GP LP, owning 27.27% of the company's shares. David V. Goeddel is also a significant insider owner.